Dr. Sameek Roychowdhury, MD

Dr. Roychowdhury practices at OSU Internal Medicine in Columbus, Ohio.

Dr. Roychowdhury's NPI, 1043332190, was assigned on April 6, 2007. Dr. Roychowdhury graduated from Ohio State University College of Medicine in 2006. Dr. Roychowdhury holds Ohio license 35.120323.

Dr. Roychowdhury's primary practice is OSU Internal Medicine, at 2050 Kenny Rd, Columbus, OH 43221 in Franklin County. The practice phone is (614) 293-2229.

Dr. Roychowdhury's primary practice is OSU Internal Medicine in Columbus, Ohio. Dr. Roychowdhury is also affiliated with Ohio State University Hospital. The medical group on file is Ohio State University Physicians. Dmand AI also links Dr. Roychowdhury to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Roychowdhury practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Roychowdhury's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Roychowdhury's licenses on file in 2 states: Ohio and Michigan.

CMS data shows 192 Medicare services from Dr. Roychowdhury across 1 procedure code in 2024, all of them office visits, for 68 Medicare patients. Medicare paid $19,970 for them. Every service was in an office.

CMS counts 68 Medicare patients who saw Dr. Roychowdhury in 2024. The largest group is 65 to 74, with 33 patients. 66% of them have high cholesterol, and 60% have high blood pressure. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Roychowdhury's median patient age at 69, with 46% women.

In 2024, Dr. Roychowdhury wrote 223 Medicare Part D claims for 43 patients. 83% of them were for generic drugs. CMS names the drug for 132 of them, across 9 drugs with 11 or more claims each, at $327,099 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

Dr. Roychowdhury accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Roychowdhury as offering telehealth.

Dmand AI links 58 papers to Dr. Roychowdhury, published from 2011 to 2025. 2019 was the busiest year, with 7. The most frequent topics are Biomarkers, Tumor, Genomics and High-Throughput Nucleotide Sequencing. Dr. Roychowdhury has published most often in JCO Precis Oncol. Dr. Roychowdhury's most frequent co-authors are Hui-Zi Chen, MD, PhD, Senthilkumar Damodaran, MD, PhD and Pannaga G. Malalur, MD.

Dmand AI links Dr. Roychowdhury to 4 clinical trials, 4 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Cholangiocarcinoma, Neoplasm Metastasis and Brain Neoplasms. Sameek Roychowdhury sponsors the most, 3.

CMS Open Payments shows 45 general payments to Dr. Roychowdhury from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Incyte Corporation paid the most, $18,373. It also lists 4 research payments totaling $4,546 in 2022.

Dr. Roychowdhury graduated from Ohio State University College of Medicine in 2006.